Literature DB >> 6321559

Increased angiotensin-converting enzyme activities in diabetes mellitus: analysis of diabetes type, state of metabolic control and occurrence of diabetic vascular disease.

G Schernthaner, C Schwarzer, R Kuzmits, M M Müller, U Klemen, H Freyler.   

Abstract

Serum angiotensin-converting enzyme activities were measured in 41 type 1 diabetics (16.4 +/- 4.0 U/ml), in 40 type 2 diabetics (15.0 +/- 5.2 U/ml) and in 52 controls (13.0 +/- 2.7 U/ml, mean +/- SD). Twenty six (32%) of 81 patients presented with serum angiotensin-converting enzyme activities above the normal range. No relation between serum angiotensin-converting enzyme activities and the presence or lack of diabetic vascular diseases in type 1 and type 2 diabetics could be detected. No significant differences in serum angiotensin-converting enzyme activities were found when comparing various types of diabetic vascular disease (retinopathy, neuropathy, renal failure, arterial vascular disease, diabetic vascular disease, coronary artery disease). However, mean serum angiotensin-converting enzyme activities were significantly increased in diabetics with retinopathy when compared with controls (p less than 0.0005). Correlation between metabolic long term control as determined by measuring glycohaemoglobin (HbA1) concentrations and serum angiotensin-converting enzyme activities could not be established. Serum angiotensin-converting enzyme activities did not show any correlations with duration of diabetes, age or sex of patients. A representative number of diabetics (32%) showed elevated serum angiotensin-converting enzyme activities, but a correlation with diabetic vascular disease, metabolic control or type of disease could not be established.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6321559      PMCID: PMC498705          DOI: 10.1136/jcp.37.3.307

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  19 in total

1.  Elevation of serum angiotensin-converting enzyme in Gaucher's disease.

Authors:  J Lieberman; E Beutler
Journal:  N Engl J Med       Date:  1976-06-24       Impact factor: 91.245

2.  Angiotensin-converting enzyme and lysozyme in silicosis and asbestosis.

Authors:  C Grönhagen-Riska; K Kurppa; F Fyhrquist; O Selroos
Journal:  Scand J Respir Dis       Date:  1978-08

Review 3.  Relation of diabetic control to development of microvascular complications.

Authors:  G Tchobroutsky
Journal:  Diabetologia       Date:  1978-09       Impact factor: 10.122

4.  The ability of various insulins and insulin fragments to inhibit the angiotensin I converting enzyme.

Authors:  J Bing; K Poulsen; J Markussen
Journal:  Acta Pathol Microbiol Scand A       Date:  1974-11

5.  Angiotensin-converting enzyme in diseases of the liver.

Authors:  K Matsuki; T Sakata
Journal:  Am J Med       Date:  1982-10       Impact factor: 4.965

6.  Effect of multiple daily insulin injections on the course of diabetic retinopathy.

Authors:  E Eschwege; C Guyot-Argenton; J P Aubry; G Tchobroutsky
Journal:  Diabetes       Date:  1976-05       Impact factor: 9.461

7.  A rapid micro-scale method for the measurement of Haemoglobin A1(a+b+c).

Authors:  S G Welch; B J Boucher
Journal:  Diabetologia       Date:  1978-03       Impact factor: 10.122

8.  Delayed progression of diabetic retinopathy by divided insulin administration: a further follow-up.

Authors:  E Eschwege; D Job; C Guyot-Argenton; J P Aubry; G Tchobroutsky
Journal:  Diabetologia       Date:  1979-01       Impact factor: 10.122

9.  Serum angiotensin-converting enzyme (SACE) in sarcoidosis and other granulomatous disorders.

Authors:  P Studdy; R Bird; D G James
Journal:  Lancet       Date:  1978 Dec 23-30       Impact factor: 79.321

10.  Elevation of serum angiotensin-converting enzyme activity in patients with hyperthyroidism.

Authors:  Y Nakamura; T Takeda; M Ishii; K Nishiyama; M Yamakada; Y Hirata; K Kimura; S Murao
Journal:  J Clin Endocrinol Metab       Date:  1982-11       Impact factor: 5.958

View more
  4 in total

1.  Resolution of Crohn's disease and complex regional pain syndrome following treatment of paratuberculosis.

Authors:  J Todd Kuenstner; William Chamberlin; Saleh A Naser; Michael T Collins; Coad Thomas Dow; John M Aitken; Stuart Weg; Grzegorz Telega; Kuruvilla John; David Haas; Torsten M Eckstein; Maher Kali; Christine Welch; Thomas Petrie
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

2.  Response of serum angiotensin converting enzyme, plasma renin activity and plasma aldosterone to conventional dialysis in patients on chronic haemodialysis.

Authors:  C Letizia; S Mazzaferro; S Morabito; A De Ciocchis; S Cerci; C D'Ambrosio; G A Cinotti; D Scavo
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

3.  Losartan improves impaired nitric oxide synthase-dependent dilatation of cerebral arterioles in type 1 diabetic rats.

Authors:  Denise M Arrick; Glenda M Sharpe; Hong Sun; William G Mayhan
Journal:  Brain Res       Date:  2008-03-21       Impact factor: 3.252

4.  Urinary angiotensin-converting enzyme activity in type 2 diabetes mellitus: its relationship to diabetic nephropathy.

Authors:  E Miyauchi; H Hosojima; S Morimoto
Journal:  Acta Diabetol       Date:  1995-10       Impact factor: 4.280

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.